INO

Inovio Pharmaceuticals, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.21
52-Week Range: $0.56 – $2.72
Market Cap: $119.94M
P/E (TTM): —
EPS (TTM): -0.90
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 21.89
PEG Ratio: —
Return on Equity: -409.87%
Return on Assets: -84.23%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 1.00
Debt/Equity: 1.83
Total Debt: $8.00M
Free Cash Flow: $-33.86M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $91.27M

INO Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$10.26M	$832.01K	$217.76K	$65.34K
Research & Development	$187.65M	$86.68M	$75.62M	$54.21M
Selling, General & Admin	$90.19M	$47.58M	$37.00M	$32.68M
Operating Expenses	$277.84M	$134.26M	$112.62M	$86.89M
Operating Income	-$267.57M	-$133.43M	-$112.40M	-$86.82M
EBITDA	-$270.90M	-$130.39M	-$103.95M	-$81.96M
Pretax Income	-$277.65M	-$135.12M	-$107.25M	-$84.95M
Net Income	-$279.82M	-$135.12M	-$107.25M	-$84.95M
Diluted EPS	-14.04	-6.09	-3.95	-1.81
Diluted Shares	19.89M	22.17M	27.16M	46.89M

INO Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$46.33M	$14.31M	$65.81M	$44.27M
Receivables	$11.74M	$2.41M	$1.20M	$450.00
Current Assets	$315.24M	$153.11M	$97.83M	$61.12M
Total Assets	$348.53M	$170.95M	$113.20M	$74.31M
Current Liabilities	$96.87M	$42.57M	$35.33M	$43.67M
Long-Term Debt	$16.61M	—	—	—
Total Debt	$32.07M	$30.21M	$11.87M	$9.37M
Total Liabilities	$126.17M	$53.60M	$44.69M	$50.21M
Retained Earnings	-$1.49B	-$1.62B	-$1.73B	-$1.82B
Shareholders' Equity	$222.36M	$117.35M	$68.50M	$24.10M
Working Capital	$218.37M	$110.54M	$62.50M	$17.45M
Net Debt	—	$2.46M	—	—

INO Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$216.22M	-$124.37M	-$104.08M	-$88.63M
Capital Expenditure	-$969.15K	-$320.90K	-$487.83K	-$285.70K
Free Cash Flow	-$217.18M	-$124.69M	-$104.56M	-$88.92M
Depreciation & Amortisation	$5.50M	$3.50M	$3.13M	$2.99M
Stock-Based Compensation	$22.56M	$11.07M	$6.60M	$3.76M
Investing Cash Flow	$109.59M	$87.36M	$104.07M	$14.04M
Financing Cash Flow	$81.84M	$5.00M	$51.48M	$53.05M
Net Change in Cash	-$24.79M	-$32.01M	$51.47M	-$21.54M

INO Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$65.34K	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$16.09M	$14.52M	$13.33M	$10.26M	$14.07M	$10.83M
Selling, General & Admin	$9.02M	$8.56M	$7.88M	$7.22M	$7.88M	$7.80M
Operating Expenses	$25.12M	$23.08M	$21.21M	$17.48M	$21.95M	$18.62M
Operating Income	-$25.05M	-$23.08M	-$21.21M	-$17.48M	-$21.95M	-$18.62M
EBITDA	-$24.31M	-$22.34M	-$44.75M	$4.52M	-$21.20M	-$17.86M
Pretax Income	-$19.69M	-$23.52M	-$45.50M	$3.76M	-$19.68M	-$6.01M
Net Income	-$19.69M	-$23.52M	-$45.50M	$3.76M	-$19.68M	-$6.01M
Diluted EPS	-0.51	-0.61	-0.87	—	-0.28	-0.07
Diluted Shares	38.61M	38.83M	52.17M	—	69.10M	81.62M

INO Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$39.92M	$24.35M	$36.57M	$44.27M	$26.27M	$31.53M
Receivables	$1.31M	$840.31K	$978.59K	$450.00	—	—
Current Assets	$71.89M	$52.70M	$55.18M	$61.12M	$39.44M	$39.91M
Total Assets	$87.27M	$68.24M	$69.39M	$74.31M	$49.78M	$49.39M
Current Liabilities	$27.33M	$31.71M	$69.82M	$43.67M	$37.92M	$39.92M
Total Debt	$11.27M	$10.66M	$10.02M	$9.37M	$8.70M	$8.00M
Total Liabilities	$36.02M	$39.71M	$77.11M	$50.21M	$43.71M	$45.02M
Retained Earnings	-$1.75B	-$1.77B	-$1.82B	-$1.82B	-$1.83B	-$1.84B
Shareholders' Equity	$51.25M	$28.53M	-$7.72M	$24.10M	$6.07M	$4.37M
Working Capital	$44.57M	$20.99M	-$14.64M	$17.45M	$1.52M	-$1.81K

INO Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$26.87M	-$20.81M	-$21.57M	-$19.37M	-$21.59M	-$18.05M
Capital Expenditure	-$59.37K	-$30.93K	-$67.95K	-$127.44K	—	—
Free Cash Flow	-$26.93M	-$20.84M	-$21.64M	-$19.50M	-$21.59M	-$18.05M
Depreciation & Amortisation	$743.45K	$741.67K	$749.66K	$754.05K	$745.46K	$765.89K
Stock-Based Compensation	$1.40M	$834.79K	$757.09K	$764.56K	$698.74K	$768.44K
Investing Cash Flow	-$51.75K	$5.28M	$8.87M	-$58.19K	$2.64M	$6.15M
Financing Cash Flow	$1.03M	-$34.78K	$24.92M	$27.13M	$953.79K	$17.16M
Net Change in Cash	-$25.90M	-$15.56M	$12.22M	$7.71M	-$18.00M	$5.25M

Market Snapshot

About

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company's proprietary DNA medicines platform uses precisely designed DNA plasmids delivered through electroporation devices to activate immune responses against specific diseases. Inovio's pipeline includes vaccine candidates for human papillomavirus (HPV)-related diseases, various cancers, and infectious diseases including COVID-19 and Lassa fever. The company collaborates with academic institutions, government agencies, and pharmaceutical partners to advance its clinical programs.